Heterocyclic Compounds as Novel Anti-cancer Agents and Their Mechanisms of Action
A special issue of Biomolecules (ISSN 2218-273X).
Deadline for manuscript submissions: 31 January 2025 | Viewed by 133
Special Issue Editors
Interests: small-molecule drug discovery; medicinal chemistry; proteolysis-targeting chimeras (PROTACs); targeted protein degradation (TPD); chemical biology; CNS drug discovery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The development of next-generation cancer therapies is crucial for identifying new targets and advancing precision oncology. Cancer remains a major concern and a leading cause of human suffering. Every year, the number of cancer cases and deaths continues to rise, posing a significant danger to public health and healthcare systems worldwide. The study of pathways, mechanisms, and structures of anticancer chemical compounds has played a crucial role in cancer prevention and treatment. Identifying different tumor cell lines and assessing the impact of natural and synthetic anticancer compounds has led to significant success. However, current therapy still faces challenges, such as the toxicity of anticancer agents and the damage they cause to normal tissues. There is an urgent need to develop potential anticancer agents with fewer off-target effects. This call for submissions includes novel anticancer heterocyclic compounds from both synthetic and natural sources, validated through in vitro or in vivo assessments of their mechanisms of action. Authors are invited to submit original research articles and review articles focused on "Heterocyclic Compounds as Novel Anti-cancer Agents and Their Mechanisms of Action.
Dr. Chandra Mishra
Dr. Dnyaneshwar N. Garad
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- heterocyclic compounds
- anticancer
- synthetic
- natural
